Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HSV thymidine kinase gene therapy

Next Previous
Drug Profile

HSV thymidine kinase gene therapy

Alternative Names: Retrovector™

Latest Information Update: 22 Jul 2010

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AVAX Technologies; Edison Biotechnology Institute; Novartis; Scientific Institute San Raffaele; Universite Pierre et Marie Curie
  • Developer AVAX Technologies; Aventis Gencell; Edison Biotechnology Institute; Human Gene Therapy Research Institute (Des Moines); Novartis; Scientific Institute San Raffaele
  • Class Gene therapies
  • Mechanism of Action Thymidine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Brain cancer; Glioma; Graft-versus-host disease; Leukaemia; Liver cancer; Lymphoma; Malignant melanoma; Mesothelioma; Multiple myeloma; Ovarian cancer; Renal cancer

Most Recent Events

  • 20 Apr 2006 Chiron Corporation has been acquired and merged into Novartis
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 20 May 2002 Interneuron Pharmaceuticals is now called Indevus Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top